Most HR positive women are on an AI for 5 to 10 years. My oncologist says I have to stay on Letrozole, or another AI, for the rest of my life since my 2nd breast cancer is a very aggressive stage 3C. She said it's common for higher risk women to have a recurrence during the first few years after they stop taking an AI and their hormone levels increase.
August 17 (edited)
It's really common to hear different opinions on this — and honestly, it can feel frustrating when your care team isn't all on the same page!
The standard duration for letrozole is typically 5 years, which is what most major clinical trials have been based on. However, some oncologists recommend extended therapy of up to Show Full Answer
It's really common to hear different opinions on this — and honestly, it can feel frustrating when your care team isn't all on the same page!
The standard duration for letrozole is typically 5 years, which is what most major clinical trials have been based on. However, some oncologists recommend extended therapy of up to 10 years for certain patients, particularly those at higher risk of recurrence. The decision often depends on individual factors, such as:
- Stage and grade of the original breast cancer
- Lymph node involvement
- Overall health and tolerance of the medication
- Risk of recurrence based on tumor characteristics
The extended 10-year approach may offer added protection against recurrence for some, but it also means more time dealing with potential side effects like bone thinning, joint pain, and other symptoms.
Since opinions can genuinely differ, it's worth having a detailed conversation with your oncologist about your specific risk profile. Asking them to walk through the pros and cons for *your* situation — not just general guidelines — can help make the decision feel much clearer.
August 17
Join
Your Privacy Choices
